Becton, Dickinson and Company (NYSE:BDX) Shares Acquired by Bokf Na

Bokf Na grew its stake in Becton, Dickinson and Company (NYSE:BDX) by 3.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,632 shares of the medical instruments supplier’s stock after buying an additional 293 shares during the period. Bokf Na’s holdings in Becton, Dickinson and Company were worth $2,107,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Magnetar Financial LLC acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at $75,493,000. Lazard Asset Management LLC boosted its holdings in shares of Becton, Dickinson and Company by 96,125.0% in the 1st quarter. Lazard Asset Management LLC now owns 3,849 shares of the medical instruments supplier’s stock valued at $952,000 after buying an additional 3,845 shares in the last quarter. Epoch Investment Partners Inc. boosted its holdings in shares of Becton, Dickinson and Company by 1.2% in the 1st quarter. Epoch Investment Partners Inc. now owns 14,939 shares of the medical instruments supplier’s stock valued at $3,697,000 after buying an additional 184 shares in the last quarter. Longview Partners Guernsey LTD boosted its stake in Becton, Dickinson and Company by 7.9% during the 1st quarter. Longview Partners Guernsey LTD now owns 2,321,435 shares of the medical instruments supplier’s stock worth $574,439,000 after purchasing an additional 170,500 shares during the period. Finally, Canada Pension Plan Investment Board boosted its stake in Becton, Dickinson and Company by 15.6% during the 1st quarter. Canada Pension Plan Investment Board now owns 280,193 shares of the medical instruments supplier’s stock worth $69,334,000 after purchasing an additional 37,851 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the sale, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the sale, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Thomas J. Spoerel sold 300 shares of Becton, Dickinson and Company stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $239.31, for a total transaction of $71,793.00. Following the sale, the senior vice president now owns 1,976 shares of the company’s stock, valued at $472,876.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 8,615 shares of company stock worth $2,033,381. Insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Stifel Nicolaus increased their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday. Evercore ISI decreased their price target on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Monday, July 15th. Barclays increased their price target on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research note on Monday, May 6th. Finally, Citigroup decreased their price target on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $280.13.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock traded up $4.52 during mid-day trading on Friday, hitting $237.30. The stock had a trading volume of 1,384,408 shares, compared to its average volume of 1,257,695. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $286.46. The firm has a market cap of $68.58 billion, a PE ratio of 52.27, a PEG ratio of 2.08 and a beta of 0.42. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.97. The company’s 50-day simple moving average is $232.24 and its 200-day simple moving average is $236.16.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, beating the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The firm had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. During the same quarter last year, the business earned $2.86 earnings per share. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. Sell-side analysts anticipate that Becton, Dickinson and Company will post 13.04 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be paid a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.60%. The ex-dividend date of this dividend is Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.